Personalizing carbamazepine therapy
نویسندگان
چکیده
منابع مشابه
Viewpoint: Personalizing Statin Therapy
Cardiovascular disease (CVD), associated with vascular atherosclerosis, is the major cause of death in Western societies. Current risk estimation tools, such as Framingham Risk Score (FRS), based on evaluation of multiple standard risk factors, are limited in assessment of individual risk. The majority (about 70%) of the general population is classified as low FRS where the individual risk for ...
متن کاملPersonalizing therapy for ovarian cancer
Ovarian cancer is the fifth largest cause of cancer-related death in females in the USA [1]. It is estimated that 15,000 women died from ovarian cancer in 2009. These dismal statistics result, in part, from the advanced stage at which ovarian cancer is diagnosed. The symptoms for ovarian cancer, which include abdominal or pelvic discomfort, urinary frequency, bloating or early satiety, are ofte...
متن کاملHyponatraemia during low-dose carbamazepine therapy.
We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures. Although asymptomatic, the biochemical abnormality improved after discontinuation of carbamazepine. Hyponatraemia developed after rechallenge with controlled release carbamazepine. The authors suggest that...
متن کاملCase Report : Carbamazepine Therapy in Schizophrenia
9 cases of schizophrenia meeting Spitzer's Research Diagnostic Criteria and nonrespondent to conventional treatment were treated with carbamazepine, either alone or in combination with neuroleptics and 7 cases had shown improvement.
متن کاملThe BATTLE trial: personalizing therapy for lung cancer.
UNLABELLED The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non-small cell lung cancer (NSCLC) patients were adaptively randomized to er...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Genome Medicine
سال: 2011
ISSN: 1756-994X
DOI: 10.1186/gm243